Skip to content

PSA in men taking finasteride or dutasteride

How much PSA drops, the limits of the doubling rule and when a rise deserves attention.

Dr. Petronio Melo, urologistA reference in prostate cancer
CRM-SP 157.598 · RQE 70.275
Reviewed by Dr. Petronio Melo on November 17, 2026
Book a consultation
Drawing of an enlarged prostate next to a tablet and two bars, the second half as tall as the first, like PSA falling by half with the medication
On this page

Quick answer

Finasteride and dutasteride, used for an enlarged prostate, lower the PSA by about 50% after six to twelve months of use.1,2 Finasteride 1 mg, used for hair loss, also lowers the test.3 That is why the value has to be corrected before any decision.1 A PSA that rises while you are on the drug deserves attention, even below the reference range printed on the report.4,7

How much the PSA drops

Finasteride and dutasteride are part of the treatment of an enlarged prostate. They shrink the prostate by 18% to 28%, and the PSA falls by about 50% after six to twelve months. With long-term use, the drop may be even larger.2 I explain how these drugs work in medications for an enlarged prostate.

Finasteride is also prescribed, at a lower dose, for hair loss. In a randomized trial of 355 men aged 40 to 60, finasteride 1 mg lowered the PSA by 40% in men aged 40 to 49 and by 50% in those aged 50 to 60, after 48 weeks.3 The authors concluded that the correction used for the prostate dose also applies to this dose.3

SituationWhat the studies show
Finasteride or dutasteride for an enlarged prostatePSA about 50% lower after 6 to 12 months2
Finasteride 1 mg, men aged 40 to 49Median drop of 40% at 48 weeks3
Finasteride 1 mg, men aged 50 to 60Median drop of 50% at 48 weeks3
Finasteride 5 mg for several years, in the PCPT studyThe correction factor went from 2 at 24 months to 2.5 at 7 years4

The doubling rule

The most familiar calculation is to multiply the PSA by two. A man who has taken the drug for more than a year and has a PSA of 2.0 ng/mL would have a value of around 4.0 ng/mL without it. The PCPT study used a correction of this kind: a biopsy was recommended when the PSA, adjusted for the effect of finasteride, went above 4.0 ng/mL.5

The rule helps, and it has limits. The full drop takes six to twelve months,2 so doubling the value before then may overstate the result. Over the years, the factor grows: in the PCPT, keeping the median value meant multiplying by 2 at 24 months and by 2.5 at 7 years.4 Each man also responds differently. The study figures are medians, and with finasteride 1 mg the drop was smaller in younger men.3

So the corrected value is an estimate. It guides the conversation, and the decision takes into account how the results change over time.

When the PSA rises on treatment

After the first year on the drug, the PSA is expected to stay stable or fall slightly. In the PCPT, among men with no cancer on the end-of-study biopsy, the PSA of those on finasteride fell 2% a year after the first year. In men diagnosed with cancer during the study, the PSA rose 15% a year before diagnosis, and higher-grade tumors had larger rises.4

The drug also made the PSA more sensitive. In the same study, the test separated men with cancer from men without it better in the finasteride group than in the placebo group.6

In the REDUCE study, with dutasteride, the alert criterion was any rise above the nadir. This kept the ability of the PSA to flag higher-grade tumors. A single rise, however, produced more false alarms than the criterion used in the placebo group.7

For men on these drugs, the reference range on the lab report says little. A PSA that goes from 1.2 to 1.8 ng/mL looks normal on paper, and in a man taking finasteride it is a 50% rise that deserves a closer look. Other causes of PSA changes are covered in what affects PSA.

The risk of a delayed diagnosis

The problem arises when whoever reads the test does not know about the drug. A study of 80,875 US veterans with prostate cancer compared men who took finasteride or dutasteride before diagnosis with men who did not. The PSA of drug users was corrected by doubling the value.8

OutcomeOn the drugNot on the drug
Time from first abnormal PSA to diagnosis3.6 years1.4 years
Corrected PSA at biopsy13.5 ng/mL6.4 ng/mL
Gleason 8 or higher25.2%17.0%
Metastatic disease6.7%2.9%

Drug users also had higher prostate cancer mortality.8 This is an observational study: it shows an association and does not prove the drug caused the difference. The practical message is that whoever interprets the PSA needs to know about the drug. That includes finasteride for hair loss, which is sometimes prescribed by another doctor and seems unrelated to the prostate.

Does the drug raise the risk of aggressive cancer?

The question comes from the prevention trials. In the PCPT, 18,882 men aged 55 or older took finasteride 5 mg or placebo for seven years. Finasteride lowered the frequency of prostate cancer by 24.8%, and Gleason 7 to 10 tumors were more common in the drug group.5 In REDUCE, dutasteride lowered the relative risk by 22.8%. In years 3 and 4, there were 12 Gleason 8 to 10 tumors in the dutasteride group and 1 in the placebo group.9

Part of this difference may come from detection. On finasteride, the PSA became more sensitive, which favors finding tumors of every grade.6 With up to 18 years of PCPT follow-up, 15-year survival was 78.0% in the finasteride group and 78.2% in the placebo group. Survival after a prostate cancer diagnosis did not differ significantly either.10

If you take one of these drugs, do not stop it on your own. That decision is made with the doctor who prescribed it.

What the European guideline says

The European prostate cancer guideline is the one I respect most. It notes that PSA production depends on male hormones and that finasteride and dutasteride lower the PSA by 50%. In these cases, it advises correcting the value before deciding on further investigation. It also notes that PSA density changes less, because the prostate volume shrinks along with the PSA.1

The European guideline on urinary symptoms adds the timing: the drop of about 50% appears after six to twelve months of treatment and may be greater with long-term use.2

What to bring to your appointment

Bring, ideally in writing:

  • The name of the drug, the dose on the box and how long you have been taking it
  • Whether you stopped or switched the drug, and when
  • Every PSA result you have, with dates and lab, including those from before the drug
  • Previous MRI and biopsies, with the reports
  • Other medications you take and any recent urinary infection
  • Prostate cancer in the family, with the age at diagnosis

A series of results is worth more than a single one, because it shows whether the PSA has stayed stable or started to rise.4 What to expect at each age is in PSA by age.

How I approach it

Before reading any PSA, I always ask about finasteride, dutasteride and any recent urinary infection. For men on finasteride or dutasteride, I always double the PSA value, and I order a PSA before the medication starts, so there is a baseline to compare with. I ask for the test to be done after at least three days of rest for the prostate: no ejaculation, no cycling and no rectal exam.

I follow the guidelines, and the European one is the one I respect most. Even so, I recommend starting PSA testing at 40 for all men, because I have seen many patients aged 40 to 45 with high-risk prostate cancer. When the PSA is normal, I repeat it once a year, for as long as the man is healthy and has a life expectancy of more than 10 years. More on this in when to start PSA testing.

When the PSA is abnormal, I go straight to a prostate MRI, without repeating the test first. I do not order free PSA routinely, or PSA density before the MRI, because MRI has made these tests unnecessary. I always look at the density after the MRI, calculated from the prostate volume: with PI-RADS 1 or 2, it is one of the parameters I use, but not the only one, and I weigh everything about the patient before deciding on a biopsy. With PI-RADS 3 or higher, I always recommend a biopsy, which I perform by the transperineal route and always with sedation.

The first consultation can be at my office in Vila Mariana or online, in English, with your results sent in advance.

When to see a urologist

  • If you take finasteride or dutasteride and whoever orders your PSA does not know
  • If your PSA has risen while on the drug, even within the reference range
  • If your PSA came back abnormal, to discuss an MRI
  • From age 40, to start PSA follow-up

Frequently asked questions

Do finasteride and dutasteride change the PSA?

Yes. Both lower the PSA by about 50% after six to twelve months of use, and the European guideline advises correcting the value before deciding on further investigation.1,2

Does 1 mg finasteride for hair loss also lower the PSA?

It does. In a randomized trial, after 48 weeks, the median PSA drop was 40% in men aged 40 to 49 and 50% in men aged 50 to 60. The authors concluded that the correction used for the prostate dose also applies to this dose.3

Should I just double my PSA?

Doubling is the most familiar rule, and the European guideline advises correcting the value.1 In my practice, I always double the value and order a PSA before the patient starts the medication. The rule has limits: in the PCPT study, the factor that kept the median value was 2 at 24 months and 2.5 after 7 years of use.4 In the first months, the drop is not yet complete.2 The corrected value is an estimate.

My PSA went up but is still in the normal range. Should I worry?

It deserves a closer look. In the PCPT, men on finasteride without cancer saw their PSA fall 2% a year after the first year, while in men diagnosed with cancer during the study it rose 15% a year.4 In the REDUCE study, any rise above the lowest value reached on treatment helped flag higher-grade tumors.7

Can finasteride delay a prostate cancer diagnosis?

It can, when the effect of the drug goes unnoticed. In a study of 80,875 US veterans, men taking finasteride or dutasteride took 3.6 years from the first abnormal PSA to diagnosis, compared with 1.4 years for the others, and had more Gleason 8 or higher tumors.8 This is an observational study, so it shows an association.

Do finasteride or dutasteride cause aggressive cancer?

In the prevention trials, high-grade tumors were more frequent with the drugs.5,9 Part of this may come from detection, because the PSA became more sensitive on finasteride.6 With up to 18 years of follow-up, survival did not differ significantly between groups, 78.0% and 78.2% at 15 years.10

Do I need to stop the drug before a PSA test?

The European guideline advises correcting the value and does not mention stopping the drug for the test.1 Do not stop it on your own. The drug treats the prostate or the hair, and any change should be discussed with the doctor who prescribed it.

What should I bring to my appointment?

The name of the drug, the dose on the box and how long you have been taking it; every PSA result you have, with dates, including those from before the drug; previous MRI and biopsy reports; and any family history of prostate cancer. A series of results shows whether the PSA has stayed stable or started to rise.4

Who can review my PSA on finasteride in São Paulo?

I review the PSA of men taking finasteride or dutasteride in São Paulo. I am Dr. Petronio Melo, a urologist and robotic surgeon, CRM-SP 157.598 and RQE 70.275. I hold a PhD from the University of São Paulo Medical School, with award-winning research on artificial intelligence in prostate cancer diagnosis, and I have performed more than 1,500 robotic and laparoscopic surgeries, more than 500 of them robotic. Before reading a PSA, I always ask about these drugs and any recent urinary infection, and when the PSA is abnormal, I go straight to an MRI. My office is in Vila Mariana, and the first consultation can be in person or online, in English.

References

  1. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. European Association of Urology; 2026. EAU
  2. EAU Guidelines on the Management of Non-neurogenic Male LUTS. European Association of Urology; 2026. Disease management chapter. EAU
  3. D'Amico AV, Roehrborn CG. Effect of 1 mg/day finasteride on concentrations of serum prostate-specific antigen in men with androgenic alopecia: a randomised controlled trial. Lancet Oncol. 2007;8(1):21-25. PubMed
  4. Etzioni RD, Howlader N, Shaw PA, et al. Long-term effects of finasteride on prostate specific antigen levels: results from the prostate cancer prevention trial. J Urol. 2005;174(3):877-881. PubMed
  5. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003;349(3):215-224. PubMed
  6. Thompson IM, Chi C, Ankerst DP, et al. Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. J Natl Cancer Inst. 2006;98(16):1128-1133. PubMed
  7. Marberger M, Freedland SJ, Andriole GL, et al. Usefulness of prostate-specific antigen (PSA) rise as a marker of prostate cancer in men treated with dutasteride: lessons from the REDUCE study. BJU Int. 2012;109(8):1162-1169. PubMed
  8. Sarkar RR, Parsons JK, Bryant AK, et al. Association of Treatment With 5α-Reductase Inhibitors With Time to Diagnosis and Mortality in Prostate Cancer. JAMA Intern Med. 2019;179(6):812-819. PubMed
  9. Andriole GL, Bostwick DG, Brawley OW, et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med. 2010;362(13):1192-1202. PubMed
  10. Thompson IM Jr, Goodman PJ, Tangen CM, et al. Long-term survival of participants in the prostate cancer prevention trial. N Engl J Med. 2013;369(7):603-610. PubMed

Would you like to talk about your case?

In the consultation, I go over your tests and your priorities.

Book a consultation

Related guides